| Publication type: | Article in scientific journal |
| Type of review: | Peer review (publication) |
| Title: | Approaching target selectivity by de novo drug design |
| Authors: | Fischer, Thomas Gazzola, Silvia Riedl, Rainer |
| et. al: | No |
| DOI: | 10.1080/17460441.2019.1615435 |
| Published in: | Expert Opinion on Drug Discovery |
| Volume(Issue): | 14 |
| Issue: | 8 |
| Page(s): | 791 |
| Pages to: | 803 |
| Issue Date: | 10-Jun-2019 |
| Publisher / Ed. Institution: | Taylor & Francis |
| ISSN: | 1746-0441 1746-045X |
| Language: | English |
| Subjects: | Drug design; Fragment-based drug design; Ligand-based drug design; Medicinal chemistry; Selectivity; Structure-based drug design; Drug development; Drug discovery; Humans; Ligands; Structure-activity relationship; Molecular targeted therapy |
| Subject (DDC): | 615: Pharmacology and therapeutics |
| Abstract: | Introduction: The development of drug candidates with a defined selectivity profile and a unique molecular structure is of fundamental interest for drug discovery. In contrast to the costly screening of large substance libraries, the targeted de novo design of a drug by using structural information of either the biological target and/or structure-activity relationship data of active modulators offers an efficient and intellectually appealing alternative. Areas covered: This review provides an overview on the different techniques of de novo drug design (ligand-based drug design, structure-based drug design, and fragment-based drug design) and highlights successful examples of this targeted approach toward selective modulators of therapeutically relevant targets. Expert opinion: De novo drug design has established itself as a very efficient method for the development of potent and selective modulators for a variety of different biological target classes. The ever-growing wealth of structural data on therapeutic targets will certainly further enhance the importance of de novo design for the drug discovery process in the future. However, a consistent use of the terminology of de novo drug design in the scientific literature should be sought. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/21748 |
| Fulltext version: | Published version |
| License (according to publishing contract): | Licence according to publishing contract |
| Departement: | Life Sciences and Facility Management |
| Organisational Unit: | Institute of Chemistry and Biotechnology (ICBT) |
| Appears in collections: | Publikationen Life Sciences und Facility Management |
Files in This Item:
There are no files associated with this item.
Show full item record
Fischer, T., Gazzola, S., & Riedl, R. (2019). Approaching target selectivity by de novo drug design. Expert Opinion on Drug Discovery, 14(8), 791–803. https://doi.org/10.1080/17460441.2019.1615435
Fischer, T., Gazzola, S. and Riedl, R. (2019) ‘Approaching target selectivity by de novo drug design’, Expert Opinion on Drug Discovery, 14(8), pp. 791–803. Available at: https://doi.org/10.1080/17460441.2019.1615435.
T. Fischer, S. Gazzola, and R. Riedl, “Approaching target selectivity by de novo drug design,” Expert Opinion on Drug Discovery, vol. 14, no. 8, pp. 791–803, Jun. 2019, doi: 10.1080/17460441.2019.1615435.
FISCHER, Thomas, Silvia GAZZOLA und Rainer RIEDL, 2019. Approaching target selectivity by de novo drug design. Expert Opinion on Drug Discovery. 10 Juni 2019. Bd. 14, Nr. 8, S. 791–803. DOI 10.1080/17460441.2019.1615435
Fischer, Thomas, Silvia Gazzola, and Rainer Riedl. 2019. “Approaching Target Selectivity by de Novo Drug Design.” Expert Opinion on Drug Discovery 14 (8): 791–803. https://doi.org/10.1080/17460441.2019.1615435.
Fischer, Thomas, et al. “Approaching Target Selectivity by de Novo Drug Design.” Expert Opinion on Drug Discovery, vol. 14, no. 8, June 2019, pp. 791–803, https://doi.org/10.1080/17460441.2019.1615435.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.